MARK3 promotes host antiviral defense by driving GEF-H1–mediated TBK1 activation
PLOS Pathogens · 2026
DOI: 10.1371/journal.ppat.1014701 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Pathogens, 2026. Verfasst von Xingmei Qi und 17 weiteren Autor:innen. Beteiligte Einrichtung: Jiangsu Key Laboratory of Infection and Immunity, Institutes of Biology and Medical Sciences, Soochow University, Suzhou, Jiangsu, China. Hauptthemen laut MEDLINE: Protein Serine-Threonine Kinases, Immunity, Innate, Rho Guanine Nucleotide Exchange Factors. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Anhui Provincial Natural Science Foundation, Research Fund of Anhui Institute of Translational Medicine.
Abstract (Originalsprache)
Innate immunity constitutes the body’s first line of defense against pathogenic challenge, serving not only as a physical and cellular bulwark that rapidly curbs microbial proliferation but also as the essential rheostat that orchestrates downstream adaptive immune responses. Here, we identified MARK3, a serine/threonine protein kinase of the conserved MARK family, as a crucial regulator of innate antiviral immunity that promotes type I interferon (IFN-I) production in a kinase-dependent manner. Using both in vitro and in vivo models, we demonstrate that MARK3 exerts broad-spectrum antiviral activity via a signaling axis involving GEF-H1 and TBK1. Mechanistically, MARK3 directly interacts with GEF-H1 and phosphorylates it at Ser645. This phosphorylation event potentiates the activation of TBK1, leading to enhanced IRF3 phosphorylation. Activated IRF3 then translocates to the nucleus, where it triggers potent IFN-I induction and the downstream expression of interferon-stimulated genes (ISGs). Our study establishes MARK3 as an important antiviral kinase and defines the MARK3–GEF-H1–TBK1 axis as a novel signaling pathway driving interferon-mediated antiviral defense.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Jiangsu Key Laboratory of Infection and Immunity, Institutes of Biology and Medical Sciences, Soochow University, Suzhou, Jiangsu, China.
- Department of Microbiology and Biotechnology, College of Life Sciences, Anhui Medical University, Hefei, China.
- Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
- Anhui Public Health Clinical Center, Hefei, China.
- School of Biological and Environmental Engineering, Jingdezhen University, Jingdezhen, China.
ORCID-Profile: Kezhen Wang
Förderung
- National Natural Science Foundation of China
- Anhui Provincial Natural Science Foundation
- Research Fund of Anhui Institute of Translational Medicine
- the Natural Science Research Projects of Anhui Provincial Universities
- Priority Academic Program Development of Jiangsu Higher Education Institutions
Zitieren
APA
Qi, X., Zhu, X., Peng, W., Hua, L., Xie, X., Si, C., Lan, M., Zhuang, Z., Ding, S., Xu, T., Li, J., Zhang, Y., Song, Y., Yang, Y., Cheng, Y., Guo, T., Li, L., & Wang, K. (2026). MARK3 promotes host antiviral defense by driving GEF-H1–mediated TBK1 activation. PLOS Pathogens. https://doi.org/10.1371/journal.ppat.1014701
Vancouver
Qi X, Zhu X, Peng W, Hua L, Xie X, Si C, et al. MARK3 promotes host antiviral defense by driving GEF-H1–mediated TBK1 activation. PLOS Pathogens. 2026. doi:10.1371/journal.ppat.1014701
BibTeX
@article{Qi2026,
author = {Qi, Xingmei and Zhu, Xue and Peng, Wenbiao and Hua, Luoxue and Xie, Xinru and Si, Chuncan and Lan, Meimei and Zhuang, Zifan and Ding, Siyi and Xu, Ting and Li, Junjie and Zhang, Yundi and Song, Yifan and Yang, Yiping and Cheng, Yixue and Guo, Tao and Li, Linchao and Wang, Kezhen},
title = {MARK3 promotes host antiviral defense by driving GEF-H1–mediated TBK1 activation},
journal = {PLOS Pathogens},
year = {2026},
doi = {10.1371/journal.ppat.1014701}
}
EUVIMED